دورية أكاديمية
أعرض في EDS

Elevated Plasma Fibrinogen Is Associated With Excessive Inflammation and Disease Severity in COVID-19 Patients.

التفاصيل البيبلوغرافية
العنوان: Elevated Plasma Fibrinogen Is Associated With Excessive Inflammation and Disease Severity in COVID-19 Patients.
المؤلفون: Sui J; Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.; Department of Hematology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China., Noubouossie DF; Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States., Gandotra S; Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States., Cao L; Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, United States.
المصدر: Frontiers in cellular and infection microbiology [Front Cell Infect Microbiol] 2021 Aug 03; Vol. 11, pp. 734005. Date of Electronic Publication: 2021 Aug 03 (Print Publication: 2021).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Media SA Country of Publication: Switzerland NLM ID: 101585359 Publication Model: eCollection Cited Medium: Internet ISSN: 2235-2988 (Electronic) Linking ISSN: 22352988 NLM ISO Abbreviation: Front Cell Infect Microbiol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Media SA
مواضيع طبية MeSH: COVID-19* , Fibrinogen*, Humans ; Inflammation ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index
مستخلص: Background: The coronavirus disease-19 (COVID-19) is characterized with intense inflammatory response, cardiac involvement, and coagulopathy. Fibrinogen, as a biomarker for inflammation, cardiovascular disease, and coagulation, has not been fully investigated yet. The aim of this study was to assess the clinical application of fibrinogen in COVID-19 patients.
Methods: We retrospectively analyzed the demographic and laboratory characteristics of 119 COVID-19 patients in the University of Alabama of Birmingham Medical Center. Correlations of fibrinogen on admission with intensive care unit (ICU) admission, disease severity, and laboratory parameters were analyzed.
Results: Among the 119 COVID-19 patients, 77.3% (92/119) had severe disease, and 59.5% (71/119) patients were admitted to the ICU. Elevated fibrinogen was detected in 67.2% (80/119) of the patients. Fibrinogen levels were significantly associated with inflammatory markers and disease severity, but not with cardiac injury biomarker high sensitivity troponin I. Patients with severe disease had increased fibrinogen levels upon admission compared to patients with non-severe disease ( P = 0.001). Fibrinogen level at 528.0 mg/dl was the optimal cutoff to predict disease severity, with a sensitivity and specificity of 66.7% and 70.3% (area undty -60er the curve [AUC] 0.72, P = 0.0006).
Conclusions: Fibrinogen is commonly elevated in COVID-19 patients, especially in those with severe disease. Elevated fibrinogen correlates with excessive inflammation, disease severity, and ICU admission in COVID-19 patients.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Sui, Noubouossie, Gandotra and Cao.)
References: ISRN Inflamm. 2012 May 06;2012:953461. (PMID: 24049653)
Lancet. 2020 Mar 28;395(10229):1054-1062. (PMID: 32171076)
J Thromb Haemost. 2020 Apr;18(4):844-847. (PMID: 32073213)
J Med Virol. 2020 Jul;92(7):791-796. (PMID: 32181911)
Expert Rev Anti Infect Ther. 2021 Mar;19(3):345-357. (PMID: 32921216)
Lancet Respir Med. 2020 Jul;8(7):681-686. (PMID: 32473124)
Can J Cardiol. 2020 Jul;36(7):1068-1080. (PMID: 32425328)
J Thromb Haemost. 2020 May;18(5):1233-1234. (PMID: 32291954)
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. (PMID: 32172226)
J Intern Med. 1990 Jun;227(6):365-72. (PMID: 2191070)
J Thromb Haemost. 2007 Mar;5(3):604-6. (PMID: 17096704)
J Clin Invest. 2020 May 1;130(5):2620-2629. (PMID: 32217835)
Nature. 2020 Mar;579(7798):270-273. (PMID: 32015507)
J Cardiovasc Risk. 1995 Jun;2(3):197-205. (PMID: 7584794)
Viral Immunol. 2021 Jun;34(5):330-335. (PMID: 32297828)
Clin Chem Lab Med. 2020 Jul 28;58(8):1191-1199. (PMID: 32432563)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
Nat Rev Immunol. 2013 Jan;13(1):34-45. (PMID: 23222502)
J Thromb Haemost. 2020 Sep;18(9):2408-2411. (PMID: 32881272)
Curr Pharm Des. 2007;13(16):1647-59. (PMID: 17584095)
Am J Cardiol. 2021 Jan 1;138:100-106. (PMID: 33058800)
Circulation. 2018 Nov 13;138(20):e618-e651. (PMID: 30571511)
J Thromb Haemost. 2020 Jul;18(7):1747-1751. (PMID: 32302448)
Clin Epidemiol Glob Health. 2021 Jul-Sep;11:100727. (PMID: 33778183)
Eur Heart J. 1996 Dec;17(12):1814-20. (PMID: 8960422)
J Am Heart Assoc. 2020 Aug 18;9(16):e017756. (PMID: 32677478)
Eur J Clin Invest. 2021 Jun;51(6):e13532. (PMID: 33660278)
JAMA Cardiol. 2020 Nov 1;5(11):1274-1280. (PMID: 32845276)
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7095-9. (PMID: 2169619)
J Card Surg. 2020 Jun;35(6):1302-1305. (PMID: 32306491)
Life Sci. 2020 Jul 15;253:117723. (PMID: 32360126)
Expert Rev Hematol. 2020 Nov;13(11):1265-1275. (PMID: 32997543)
Lancet Haematol. 2020 Jun;7(6):e438-e440. (PMID: 32407672)
Heart. 2020 Aug;106(15):1127-1131. (PMID: 32499236)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
فهرسة مساهمة: Keywords: cardiovascular disease; coagulation; coronavirus disease 2019 (COVID-19); fibrinogen; inflammation
المشرفين على المادة: 9001-32-5 (Fibrinogen)
تواريخ الأحداث: Date Created: 20210820 Date Completed: 20210826 Latest Revision: 20210826
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8369350
DOI: 10.3389/fcimb.2021.734005
PMID: 34414135
قاعدة البيانات: MEDLINE
الوصف
تدمد:2235-2988
DOI:10.3389/fcimb.2021.734005